Five-year-old Michael is one of less than 100 people in the world with SPG50, an ultrarare genetic disease. In March 2022, a SickKids team dosed Michael with the first-ever gene therapy for SPG50 in an unprecedented clinical trial.&nbsp;We tell the remarkable story of what it took to deliver a customized drug for Michael’s particular genetic variant, and what it means for SickKids’ vision of precision medicine. ﻿﻿(For bonus content or to advance similar research, please visit <a href="https://www.sickkidsfoundation.com/podcast" target="_blank" style="background-color: transparent; color: rgb(5, 99, 193);">SickKidsFoundation.com/podcast</a>. The SickKids VS Podcast is generously sponsored by CIBC and edited by Quill.)

What Happens When We Pull a Neglected Disease into the Spotlight? SickKids VS Sickle Cell Disease

Big breakthroughs often start with a simple question. SickKids VS takes you behind the scenes of remarkable discoveries to answer questions like: How can we diagnose faster? What if we could prevent cardiac death? And why do we need artificial intelligence in our hospital? Join us to heal the future.